Unquote readers and industry professionals now have the chance to have their say and vote for which firms they believe should be recognised. The poll takes place via a secure online system containing a short summary of shortlisted candidates’ successes.
Acceleris has assisted Redx Pharma and it’s predecessor through numerous funding rounds to the value of £13m under the Enterprise Investment Scheme (before the £15m IPO raise) as well as maintaining a position on the board of the company and acting as company secretary. This relationship culminated in the companies admission to the AIM market in March 2015 at a market cap of £55.2m.
Redx Pharma plc has been taken from start-up to a successful listing by Acceleris Capital and the company is now regarded as one of the leading biotechnology firms in Europe.
Redx has already established a portfolio of 13 proprietary (patent-obtected) drug programs and has been named as one of the Times Top 10 disrupters to watch since admission.
Following a recent visit by Chancellor George Osborne, the company has announced a further collaboration deal with Horizon Group plc and the share price has maintained a higher figure than on admission.
- Voting closes this Thursday (September 10th)
- Acceleris is nominated for Category 12: Venture Exit